Bayer tests drug cure for double chins
German pharmaceutical giant Bayer announced on Monday it was developing a drug to combat the dreaded double chin that it says could generate €250 million a year in sales.
A patient's double chin, sometimes called a “waddle,” would be reduced through injections of the compound ATX-101.
The company plans to study the drug’s safety and effectiveness in two studies of the cosmetic medicine. Bayer has started phase 3 trials on 720 patients around Europe, according to a company statement released this week.
“There is a huge demand for a safe, effective and approved injectable treatment for localized fat reduction,” said Jean Paul Ortonne, a dermatologist who will carry out the trials in France.
The drug to combat the curse of middle age would be given in the form of injections. It works by dissolving fat cells, known as adipocytes, while leaving surrounding tissue unaffected.
The firm believes the drug could earn €150 million to €250 million, not including even the key market of the United States.
It is hoping to have the drug licensed for sale in Europe, Asia and Latin America by 2014. The Californian cosmetic medicine firm Kythera will be responsible for the marketing of the drug in the US.
The Local/djw
Comments
See Also
A patient's double chin, sometimes called a “waddle,” would be reduced through injections of the compound ATX-101.
The company plans to study the drug’s safety and effectiveness in two studies of the cosmetic medicine. Bayer has started phase 3 trials on 720 patients around Europe, according to a company statement released this week.
“There is a huge demand for a safe, effective and approved injectable treatment for localized fat reduction,” said Jean Paul Ortonne, a dermatologist who will carry out the trials in France.
The drug to combat the curse of middle age would be given in the form of injections. It works by dissolving fat cells, known as adipocytes, while leaving surrounding tissue unaffected.
The firm believes the drug could earn €150 million to €250 million, not including even the key market of the United States.
It is hoping to have the drug licensed for sale in Europe, Asia and Latin America by 2014. The Californian cosmetic medicine firm Kythera will be responsible for the marketing of the drug in the US.
The Local/djw
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.